Skip to main content

Table 1 Community COVID-19 prevalence and asymptomatic carriage in pregnant women

From: Samba II PCR testing for COVID-19 in pregnant women: a retrospective cohort study and literature review

Author Region/Country Type of study Peak daily case load at start of the study period for relevant area Max daily case load during study period for relevant area Peak daily case load the end of the study period for relevant area Number of pregnant women in study Number tested positive Number asymptomatic at the time of admission AND tested positive Test positivity % Proportion of asymptomatic test positive %
Fassett California, USA Observational retrospective study 1261 1921 1921 3923 17 17 0.43 100.00
Gagliardi North of Tuscany and Liguria, Italy Case series 5210 6153 4053 533 3 2 0.56 66.67
Herraiz Madrid, Spain Observational retrospective study 6278 6740 2610 203 2 1 0.99 50.00
Naqvi California, USA Case series 1104 1331 1268 82 1 0 1.22 0.00
LaCourse Washington, USA Retrospective cohort 2 437 314 188 5 1 2.66 20.00
Ceulemans North East Flanders, Belgium Case series 683 2319 426 470 13 8 2.77 61.54
Miller Illinois, USA Case series 1150 2023 2023 635 23 10 3.62 43.48
Ochiai Tokyo, Japan Retrospective analysis 383 743 203 52 2 2 3.85 100.00
Campbell Connecticut, USA Case series 377 1100 620 770 30 22 3.90 73.33
Khalil London, UK Cohort study 822 1071 434 129 9 8 6.98 88.89
Yassa Istanbul, Turkey Prospective cohort 2131 2936 1035 296 23 12 7.77 52.17
Prabhu New York, USA Prospective cohort 2166 9909 6693 675 70 55 10.37 78.57
Doria Senhora da Hora, Portugal Case series 302 1516 514 103 12 11 11.65 91.67
Sutton New York, USA Cohort study 2166 8775 8775 215 33 29 15.40 87.60
Buckley New York, USA Case series 9073 9909 8064 307 50 50 16.29 100.00
Vintzileos New York, USA Retrospective cohort 6555 9909 9410 161 32 21 19.88 65.63
London New York, USA Retrospective cohort 73 9909 8064 156 68 22 43.58 32.35
  1. Data presented are in ascending order of the total proportion of pregnant women who tested positive. Data for peak daily reported COVID-19 prevalence at the start, during and end of the relevant study periods were retrieved from internationally published repositories [30,31,32]. This data was used to generate Figs. 2 and 3. NP- Nasopharyngeal, OP- Oropharyngeal